425: Scilex Holding's Semnur Pharmaceuticals Announces $2.5 Billion Merger with Denali Capital Acquisition Corp.

Semnur Pharmaceuticals, a Scilex Holding subsidiary, is set to merge with Denali Capital Acquisition Corp. in a deal valuing Semnur at $2.5 billion.

Summary

• Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, has entered into a merger agreement with Denali Capital Acquisition Corp.
• The deal values Semnur at a pre-transaction equity value of $2.5 billion.
• Following the merger, Denali will redomesticate as a Delaware corporation and change its name to Semnur Pharmaceuticals, Inc.
• The combined company's stock and warrants are expected to be listed on Nasdaq under the ticker symbols SMNR and SMNRW, respectively.
• Scilex is expected to be the majority holder of the combined company, which will be led by an experienced management team.
• The merger is expected to close in the first quarter of 2025, pending shareholder approval, regulatory approvals, and other customary closing conditions.
• Semnur's lead product, SP-102 (SEMDEXA), is a non-opioid injectable corticosteroid gel for sciatica, currently in Phase 3 development with FDA Fast Track status.
• Projected sales of SEMDEXA in sciatica are estimated to reach $1.5 billion to $2.0 billion annually by the fifth year of launch.
• Scilex's board previously authorized a potential dividend of up to 10% of its ownership in Semnur in connection with the merger, subject to SEC registration of Semnur's common stock.
• The Scilex board may determine not to proceed with the dividend.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the merger announcement, the potential of SP-102 (SEMDEXA), and the experienced management team. However, it also acknowledges risks and uncertainties, preventing a higher score.

Positives

• The merger provides Semnur with access to public markets and further investment for SP-102 (SEMDEXA) development.
• SP-102 (SEMDEXA) has promising market potential, with projected sales reaching $1.5 billion to $2.0 billion annually.
• The combined company will be led by an experienced management team.
• SP-102 (SEMDEXA) has FDA Fast Track status, potentially expediting its regulatory review.
• Scilex retains majority ownership of the combined company.

Negatives

• The merger is subject to shareholder and regulatory approvals, and other closing conditions, creating uncertainty.
• Projected sales of SP-102 (SEMDEXA) are estimates and may not be realized.
• The Scilex board may determine not to proceed with the dividend.

Risks

• The inability to consummate the business combination.
• Failure to obtain shareholder or regulatory approvals.
• Delays in the closing of the transaction.
• Failure to realize the anticipated benefits of the business combination.
• Difficulties in integrating the businesses of Semnur and Denali.
• Redemption requests made by Denalis shareholders.
• Inability to obtain or maintain the listing of the post-acquisition companys securities on Nasdaq.
• Costs related to the business combination.
• General economic, political and business conditions.
• The outcome of any legal proceedings that may be instituted against the parties following the announcement of the business combination.
• The receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the business combination.
• Failure to realize the anticipated benefits of the business combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Semnur or Denali.
• The risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination.
• The ability of the combined company to grow and manage growth profitably and retain its key employees.
• The amount of redemption requests made by Denalis shareholders.
• The inability to obtain or maintain the listing of the post-acquisition companys securities on Nasdaq following the business combination.
• Costs related to the business combination.

Future Outlook

The combined company will focus on developing and commercializing non-opioid pain management products, with SP-102 (SEMDEXA) as a key driver of future growth.

Management Comments

• Jaisim Shah, Chief Executive Officer and President of Scilex, stated that the business combination will enable the company to advance its growth strategy, including gaining access to public markets and exploring potential partnerships and global pharma collaborations for SP-102 (SEMDEXA).

Industry Context

The announcement reflects a growing trend in the biopharmaceutical industry towards non-opioid pain management solutions, addressing the opioid crisis and unmet needs in chronic pain treatment.

Comparison to Industry Standards

• It is difficult to compare the $2.5 billion valuation directly to other companies without knowing specific revenue multiples or clinical stage comparables.
• However, similar stage pharmaceutical companies with promising late-stage assets in pain management have been valued in the range of $1 billion to $5 billion.
• For example, companies like Vertex Pharmaceuticals (though much larger) have seen success in developing non-opioid pain treatments.
• The projected sales of $1.5-2.0 billion for SP-102 (SEMDEXA) would place it among the top-selling pain management drugs if achieved, comparable to some blockbuster drugs in the field.

Stakeholder Impact

• Shareholders of Scilex may benefit from the increased value of Semnur.
• Patients with sciatica may benefit from a new non-opioid treatment option.
• Employees of Semnur may have new opportunities within the combined company.

Next Steps

• Obtain approval from the SPAC's shareholders.
• Obtain any applicable regulatory approvals.
• Satisfy or waive certain other closing conditions.
• Complete the redomestication of the SPAC as a Delaware corporation.
• List the combined company's common stock and warrants on Nasdaq.

Key Dates